To access this element change to forms mode OFF
Grant Award View - GA70319
POLEM Trial: Avelumab plus fluoropyrimidine-based chemotherapy as...
GA ID:
GA70319
Agency:
Department of Health and Aged Care
Approval Date:
19-Nov-2019
Publish Date:
5-Feb-2020
Category:
Health and Medical Research
Grant Term:
1-Feb-2020 to 31-Jan-2025
Value (AUD):
$981,312.50
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF International Clinical Trials_PRC2_funding_commencing_2019
Grant Activity:
POLEM Trial: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study
Purpose:
Most people with stage III colon cancer are treated with surgery then chemotherapy to prevent cancer coming back. In some patients, unfortunately cancer does come back. This study is being conducted to assess whether adding a new drug to standard chemotherapy could reduce the risk of cancer returning. This new drug, called avelumab is an immunotherapy drug that helps the immune system attack and kill cancer cells. If positive this trial could change treatment worldwide for this patient group.
GO ID:
GO Title:
Medical Research Future Fund – International Clinical Trial Collaborations Grant Opportunity
Internal Reference ID:
MRF1191909
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA